Deucravacitinib
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2022
- First approval year
- 2022
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Deucravacitinib
- Molecular weight
- 425.47
- Structure (SMILES)
These details could not be displayed.
- sotyktu
- Sotyktu
- 6 cyclopropaneamido 4 2 methoxy 3 1 methyl 1h 1 2 4 triazol 3 yl phenyl amino n h methylpyridazine 3 carboxamide
- 6 cyclopropanecarboxamido 4 2 methoxy 3 1 methyl 1h 1 2 4 triazol 3 yl phenyl amino n methyl d sub 3 sub pyridazine 3 carboxamide
- 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d<sub>3</sub>)pyridazine-3-carboxamide
- 6-CYCLOPROPANEAMIDO-4-{[2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL]AMINO}-N-(?H?)METHYLPYRIDAZINE-3-CARBOXAMIDE
- bms 986165
- BMS 986165
- Bms-986165
- BMS-986165
- BMS-986165 Capsule
- BMS-986165 Tablet
- deucravacitinib
- Deucravacitinib
- DEUCRAVACITINIB
- DEUCRAVACITINIB (BMS-986165)
- Deucravacitinib [INN]
- Deucravacitinib [JAN]
- Deucravacitinib [MI]
- Deucravacitinib [USAN]
- Deucravacitinib [WHO-DD]
- deucravacitinib bms 986165
- deucravacitinib inn
- deucravacitinib jan
- deucravacitinib mi
- deucravacitinib usan
- deucravacitinib who dd
And 4 more, listed on the interactive page.
- ATC classification codes
- L04AF07
Sources for recorded values
- CAS registry numbers
- 1609392-27-9
- ChEMBL ID
- CHEMBL4435170
- InChIKey
- BZZKEPGENYLQSC-FIBGUPNXSA-N
- PubChem compound IDs
- 134821691
- RxNorm IDs (RxCUI)
- 2612087
- FDA ingredient codes (UNII)
- N0A21N6RAU
- Applicant
- BRISTOL
- Approval date
- 9 Sept 2022
- Application number
- NDA214958
- Status
- Authorised
- Status date
- 24 Mar 2023
- Authorisation date
- 24 Mar 2023
- Approved indications
- Plaque psoriasis Sotyktu is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis Sotyktu, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy.
- Product number
- EMEA/H/C/005755
- Authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- Yes
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Psoriasis
European medicines record
- Patents
- 4
- Designations
- 0
- Earliest recorded loss of exclusivity
- 11 Feb 2043
- First in class
- Yes
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- deucravacitinib
- Type
- Synthetic organic
- Drug name stem
- deu-; -tinib
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Janus kinase 1
- Gene symbol
- JAK1
- Protein identifier
- P23458
- Median affinity
- 9
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- tyrosine kinase 2
- Gene symbol
- TYK2
- Protein identifier
- P29597
- Median affinity
- 10.7
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- bone morphogenetic protein receptor type 2
- Gene symbol
- BMPR2
- Protein identifier
- Q13873
- Median affinity
- 6.71
- Affinity units
- pIC50
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
- Action type
- NEGATIVE_ALLOSTERIC_MODULATOR
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Protein identifier
- P29597
Open Targets mechanisms
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
- Action type
- NEGATIVE ALLOSTERIC MODULATOR
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Psoriasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Sjogren's Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000699
- Subject identifier
- D012859
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Arthritis, Psoriatic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003778
- Subject identifier
- D015535
- Condition
- Lupus Erythematosus, Cutaneous
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003834
- Subject identifier
- D008178
- Condition
- Alopecia Areata
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Vitiligo
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004208
- Subject identifier
- D014820
- Condition
- Lupus Nephritis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005761
- Subject identifier
- D008181
- Condition
- Lichen Planus
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009856
- Subject identifier
- D008010
- Condition
- Hidradenitis Suppurativa
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000710
- Subject identifier
- D017497
- Condition
- Psoriasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001494
- Subject identifier
- D011565
- Condition
- Pyoderma
- Highest recorded phase
- 0.5
- Condition identifier
- HP:0000999
- Subject identifier
- D011711
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- HP:0001410
- Subject identifier
- D008107
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition
- Pityriasis Rubra Pilaris
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100017
- Subject identifier
- D010916
- Condition
- Inflammation
- Highest recorded phase
- 1
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000540
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000676
- Condition identifier
- EFO_0000699
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003778
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004192
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004208
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009733
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009855
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009856
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001494
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 4
- Condition identifier
- HP_0000964
- Condition identifier
- HP_0000999
- Condition identifier
- HP_0000999
- Highest recorded phase
- 1
- Condition identifier
- HP_0001410
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004980
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005556
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006554
- Highest recorded phase
- 2
And 19 more, listed on the interactive page.
- NCT02931838
- NCT03004768
- NCT03419910
- NCT03611751
- NCT03624127
- NCT03873415
- NCT03924427
- NCT04036435
- NCT04167462
- NCT04772079
- NCT05124080
- NCT05478499
- NCT05701995
- NCT06042920
- NCT06281106
- NCT06329258
- NCT03044873
- NCT03956953
- NCT03252587
- NCT03541564
- NCT04065932
- NCT03881059
- NCT04908189
- NCT04908202
- NCT03890770
And 14 more, listed on the interactive page.
- Dose
- 6mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Do not crush, cut, or chew the tablets
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 3
- Polar surface area
- 135.95
- Calculated partition coefficient (ALogP)
- 1.73
- Calculated partition coefficient (XLogP)
- 1.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 31
- Molecular formula
- C20H22N8O3
- Monoisotopic mass
- 425.20031683
- Natural product
- No
- 0003-0895
- Recorded assays
- 355
- Active assays
- 87
Active assay types
- Confirmatory
- Tyrosine Kinase Inhibitors
- Dermatologic Agents
These details could not be displayed.
Related records
Trials (97)
- A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
- A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
- A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
- A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
- A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
- A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers
- A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
- A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
- A Study of Deucravacitinib to Treat LPP and FFA
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
- A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
- A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring
- A Study to Assess Deucravacitinib Safety in Pregnancy
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Approved for (2)
- Palmoplantar pustulosis
- Psoriasis
In development for (16)
- Alopecia areata Phase 2
- Cutaneous lupus erythematosus Phase 2
- Hidradenitis suppurativa Phase 2
- Immune system disorder Phase 1
- Kidney disorder Phase 1
- Lichen planus Phase 2
- Liver disorder Phase 1
- Lupus nephritis Phase 2
- Pityriasis rubra pilaris Phase 2
- Psoriasis-related juvenile idiopathic arthritis Phase 3
- Psoriatic arthritis Phase 3
- Pyoderma Early phase 1
- Sjogren syndrome Phase 3
- Systemic lupus erythematosus Phase 2
- Ulcerative colitis Phase 2
- Vitiligo Phase 3
Other linked conditions (1)
- Pustular psoriasis
Targets (1)
- TYK2 Tyrosine-protein kinase TYK2 negative allosteric modulator